Bengaluru-based genomic diagnostics and research services company MedGenome has secured $47.5 million in its Series E funding round, marking a significant milestone in expanding access to precision medicine across India and emerging markets. The round was co-led by Maj Invest, a private equity firm joining as a new investor, alongside existing investor Novo Holdings, with participation from existing shareholder Sofina.
Strategic Focus on Healthcare Transformation
The funding will enable MedGenome to broaden access to its genomics and integrated diagnostics solutions across India and other emerging markets. The company's mission centers on reducing India's disease burden through early detection and targeted disease management using genetic and integrated diagnostics tools with high affordability.
"India's healthcare ecosystem is increasingly recognizing the transformative potential of genomics, driving innovation and enhancing the country's healthcare capabilities," said Dr. Vedam Ramprasad, CEO of MedGenome. "This fundraise also reflects the growing adoption of genomics in personalized and preventive healthcare in India as well as other emerging economies."
Precision Medicine Platform
MedGenome positions itself as a science-led platform that combines cutting-edge science with real-world application, bringing advanced omics solutions that bridge unmet needs in disease diagnosis and management. According to Dr. Ramprasad, early genomics-led intervention not only helps patients but also helps families manage the economic and emotional burden of disease.
Investor Confidence in Genomics Market
Dr. Amit Kakar, Managing Partner and Head of Asia at Novo Holdings and Chairman of the Board of MedGenome, emphasized the strategic importance of the investment. "Our reinvestment in MedGenome reflects our belief in the company's potential to transform the landscape of genetic and integrated diagnostics in India and beyond," he stated. "MedGenome stands out as a science-led platform with strong fundamentals, and this investment aligns with our conviction in the growing importance of genomics and personalised healthcare across emerging markets."
Jannick Dam Mortensen, Partner at Maj Invest Minorities, highlighted MedGenome's track record in driving innovation. "With its robust genomics portfolio, commitment to science and the transformative impact it has had on healthcare, MedGenome has consistently demonstrated its ability to drive innovation and precision diagnostics," he said. "We're proud to support their next phase of growth, expanding their solutions to more markets in India and worldwide."
Market Expansion Strategy
The Series E funding represents over ₹409 crore and positions MedGenome to capitalize on the growing adoption of genomics in personalized and preventive healthcare across emerging economies. The company's integrated approach to genomic diagnostics and research services aims to make precision medicine more accessible and affordable in markets where such technologies have traditionally been limited.
